# Urticaria and Related Conditions

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/urticaria-and-related-conditions/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, classification, and management of urticaria, particularly chronic spontaneous urticaria. It explores the role of autoimmune factors, the effectiveness of treatments like omalizumab, and the impact on quality of life. Additionally, it delves into the association with thyroid autoimmunity and the use of autoantibodies as markers for diagnosis. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12438 |
| Works | 201 |

## Topic papers all

Showing 15 of 201.

- [2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia](https://scholariq.org/papers/2012-american-college-of-rheumatology-guidelines-for-management-of-gout-part-1/)
- [The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria](https://scholariq.org/papers/the-eaaci-ga2len-edf-wao-guideline-for-the-definition-classification-diagnosis-2/)
- [Small-Vessel Vasculitis](https://scholariq.org/papers/small-vessel-vasculitis/)
- [HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol](https://scholariq.org/papers/hla-b-5801-allele-as-a-genetic-marker-for-severe-cutaneous-adverse-reactions/)
- [The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria](https://scholariq.org/papers/the-international-eaaci-ga2len-euroguiderm-apaaaci-guideline-for-the-definition/)
- [EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis](https://scholariq.org/papers/eular-era-edta-recommendations-for-the-management-of-anca-associated-vasculitis/)
- [The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update](https://scholariq.org/papers/the-scp-eaaci-scp-scp-ga-scp-sup-2-sup-scp-len-scp-scp-edf-scp-scp-wao-scp/)
- [Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis](https://scholariq.org/papers/randomized-trial-of-plasma-exchange-or-high-dosage-methylprednisolone-as/)
- [2020 American College of Rheumatology Guideline for the Management of Gout](https://scholariq.org/papers/2020-american-college-of-rheumatology-guideline-for-the-management-of-gout-2/)
- [Pathogenesis of Gout](https://scholariq.org/papers/pathogenesis-of-gout/)
- [The diagnosis and management of acute and chronic urticaria: 2014 update](https://scholariq.org/papers/the-diagnosis-and-management-of-acute-and-chronic-urticaria-2014-update/)
- [IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC–activated Th2 memory cells](https://scholariq.org/papers/il-25-augments-type-2-immune-responses-by-enhancing-the-expansion-and-functions/)
- [Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin](https://scholariq.org/papers/proteinase-activated-receptor-2-mediates-itch-a-novel-pathway-for-pruritus-in/)
- [Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE.](https://scholariq.org/papers/prostaglandin-d2-generation-after-activation-of-rat-and-human-mast-cells-with/)
- [Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus](https://scholariq.org/papers/assessment-of-pruritus-intensity-prospective-study-on-validity-and-reliability/)

## Topic primary papers

Showing 15 of 55.

- [The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria](https://scholariq.org/papers/the-eaaci-ga2len-edf-wao-guideline-for-the-definition-classification-diagnosis-2/)
- [The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria](https://scholariq.org/papers/the-international-eaaci-ga2len-euroguiderm-apaaaci-guideline-for-the-definition/)
- [The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update](https://scholariq.org/papers/the-scp-eaaci-scp-scp-ga-scp-sup-2-sup-scp-len-scp-scp-edf-scp-scp-wao-scp/)
- [The diagnosis and management of acute and chronic urticaria: 2014 update](https://scholariq.org/papers/the-diagnosis-and-management-of-acute-and-chronic-urticaria-2014-update/)
- [The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update](https://scholariq.org/papers/the-eaaci-ga2len-edf-wao-guideline-for-the-definition-classification-diagnosis/)
- [<scp>BSACI</scp> guideline for the management of chronic urticaria and angioedema](https://scholariq.org/papers/scp-bsaci-scp-guideline-for-the-management-of-chronic-urticaria-and-angioedema/)
- [Chronic urticaria and autoimmunity: Associations found in a large population study](https://scholariq.org/papers/chronic-urticaria-and-autoimmunity-associations-found-in-a-large-population/)
- [The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from <scp>ASSURE</scp>‐<scp>CSU</scp>](https://scholariq.org/papers/the-burden-of-chronic-spontaneous-urticaria-is-substantial-real-world-evidence/)
- [The global burden of chronic urticaria for the patient and society*](https://scholariq.org/papers/the-global-burden-of-chronic-urticaria-for-the-patient-and-society/)
- [Ligelizumab for Chronic Spontaneous Urticaria](https://scholariq.org/papers/ligelizumab-for-chronic-spontaneous-urticaria/)
- [Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study](https://scholariq.org/papers/biomarkers-and-clinical-characteristics-of-autoimmune-chronic-spontaneous/)
- [The German version of the chronic urticaria quality‐of‐life questionnaire: factor analysis, validation, and initial clinical findings](https://scholariq.org/papers/the-german-version-of-the-chronic-urticaria-quality-of-life-questionnaire-factor/)
- [Definition, aims, and implementation of <scp>GA</scp><sup>2</sup><scp>LEN</scp> Urticaria Centers of Reference and Excellence](https://scholariq.org/papers/definition-aims-and-implementation-of-scp-ga-scp-sup-2-sup-scp-len-scp-urticaria/)
- [Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients](https://scholariq.org/papers/predictors-of-response-to-omalizumab-and-relapse-in-chronic-spontaneous/)
- [Chronic Urticaria: Etiology and Natural Course in Children](https://scholariq.org/papers/chronic-urticaria-etiology-and-natural-course-in-children/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.